National Neuromuscular Research Institute

01/08/2026

How clinical research is exploring new pathways for communication in ALS🧠🔬

ALS is a progressive neurodegenerative disease that affects motor neurons, often making communication increasingly difficult over time. Research into assistive technologies, including brain computer interfaces like Neuralink, is exploring how communication may be supported in the future through clinical studies.

This KXAN story highlights one individual’s personal experience living with ALS and participating in a Neuralink clinical trial. The patient’s perspective reflects the daily challenges ALS can bring, particularly related to mobility and communication, and the importance of ongoing, ethical research in this space. We are grateful to individuals who choose to share their stories publicly and contribute to clinical research.

01/01/2026

As we welcome in this new year, we’re especially thankful for our dedicated employees and the patients who place their trust in us.
Happy New Year from all of us at NNRI 💙

12/23/2025

We’re proud to see Dr. Yessar Hussain, Director of the National Neuromuscular Research Institute and Austin Neuromuscular Center, featured in this KXAN story on ALS and emerging assistive technology, .

There is still no cure for ALS, but innovation—combined with comprehensive neuromuscular care—can help support quality of life and independence for patients and families.

Technologies like Neuralink are not treatments or cures; however, they raise important questions about how assistive technology may support communication and independence for people living with paralysis.

At NNRI and ANC, our focus remains on evidence-based care, ongoing research, and supporting patients at every stage of neuromuscular disease.




🔗 Learn more about ALS care and research at: https://austinneuromuscle.com/about/

https://www.kxan.com/news/science/neuralink-provides-austin-man-wings-after-als-diagnosis/

Jake Schneider, an ALS patient, was able to reconnect with the world through Neuralink, a brain-computer interface device that allows him to control a cursor on a screen and play video games with h…

12/23/2025

Behind every milestone is an amazing team. 💙
Thank you to our incredible NNRI staff for your hard work, compassion, and commitment to our participants—every single day.

Study Details:
https://clinicaltrials.gov/study/NCT06742190

Learn more about NNRI’s studies by visiting our website! 🧬
https://austinneuromuscle.com/clinical-research/

12/16/2025

Amyloidosis is rare—but early awareness matters.
Understanding symptoms and treatment options can help protect vital organs and improve outcomes.

At NNRI, we’re conducting a clinical trial for Hereditary TTR Amyloidosis.
Learn more about our ongoing studies at the link below🧬🔗
https://austinneuromuscle.com/clinical-research/

12/09/2025

NNRI is dedicated to understanding IMNM and exploring potential treatment options through clinical trials. 🔬🧬

Learn more about NNRI's ongoing studies at our website:
https://austinneuromuscle.com/clinical-research/

12/01/2025

Dermatomyositis is a rare disease, affecting roughly 1 in 100,000 people.

NNRI is conducting research to better understand this condition and exploring potential treatment options through clinical trials. 🧠🔬

Learn more about our ongoing studies at our website:
https://austinneuromuscle.com/clinical-research/

11/27/2025

✨💛Happy Thanksgiving! 💛✨

Thanksgiving is a time to reflect on the people who make our work so impactful. We are deeply grateful to our incredible staff, whose commitment and care make our work possible, and for our patients, who allow us to be part of their health journeys. 🦃

Wishing you all a safe and joyful holiday!

11/26/2025

At NNRI, we are dedicated to advancing research on MMN and exploring alternative treatment options through clinical trials. 🔬

Learn more about our ongoing studies:
https://austinneuromuscle.com/clinical-research/

11/21/2025

Myasthenia Gravis (MG) affects thousands of individuals across the U.S., often bringing fluctuating muscle weakness, vision changes, or difficulty with everyday tasks.
Because the signs can be subtle or resemble other conditions, meeting with experienced clinicians can play an important role in getting a timely and accurate diagnosis.

At NNRI, our team is involved in clinical trials evaluating investigational treatments for MG.
More information about MG and our research efforts is available on our website.

🔬 Learn more about our current studies at the link below.
https://austinneuromuscle.com/clinical-research/

11/14/2025

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder that affects the nerves, causing weakness, numbness, and fatigue.

At NNRI, we’re dedicated to advancing research and improving outcomes for individuals living with CIDP.

If you or someone you know has CIDP, you may qualify for a currently enrolling clinical study.

Learn more here: https://austinneuromuscle.com/clinical-research/

11/05/2025

🧬Now enrolling!🧬

Learn more at: https://clinicaltrials.gov/study/NCT06371417?term=RAY902CT&rank=1

Click here to enter your info to see if you qualify: https://austinneuromuscle.com/clinical-research/